Novartis will showcase results from multiple clinical trials of Rhapsido (remibrutinib) at the EAACI Congress 2026, including pivotal Phase III data for chronic inducible urticaria and extension data for chronic spontaneous urticaria. The presentations highlight Rhapsido's efficacy and safety across immune-mediated diseases, with additional Phase II data on food allergy. These findings could offer new treatment options for patients with limited current therapies, advancing Novartis' immunology portfolio.
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
Novartis announced that Vanrafia (atrasentan) significantly slowed kidney function decline by approximately 34% compared to placebo over 2.5 years in adults with IgA nephropathy, based on Phase III ALIGN study results published in The Lancet. The dru...
Novartis announced that its drug Cosentyx (secukinumab) demonstrated statistically significant and clinically meaningful sustained remission in patients with polymyalgia rheumatica (PMR) compared to placebo, according to Phase III REPLENISH trial dat...
